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1. Introduction 
Osteoarthritis (OA) is the most common joint-related disorder. The prevalence rises steeply 
with age and is a major cause of pain and disability. In the over 65-year-old population, 12% 
suffer from symptomatic knee OA (1) while 13– 26 % suffer from symptomatic OA in at least 
one hand joint (2). Hip OA is much less common. The prevalence of radiographic change is 
much higher; in the elderly population 75% have evidence of hand OA and 30% of knee OA 
on plain radiographs (3).  
The term “osteoarthritis” is used to refer to a number of related conditions that can be 
broadly classified into two groups.  Primary OA, which can be localised or generalised and 
more commonly affects peri-menopausal woman (especially involving the hand inter-
phalangeal joints); or secondary OA which has an underlying cause such as an 
inflammatory arthritis (e.g. rheumatoid arthritis or crystal arthritis), mechanical damage 
(e.g. articular fractures), a congenital or developmental disorder or a metabolic or endocrine 
condition (4). An osteoarthritic joint may show varying degrees of inflammatory change, 
detectable clinically and histologically. It is uncertain to what degree these (and other) 
subdivisions of OA are useful in terms of therapy. 
This chapter addresses therapies for all forms of OA of limb joints. Much of the evidence 
that will be considered here does not distinguish between the various types, although where 
possible, efficacy in knee, hip and hand OA is described separately due to the differing 
natural history and prognosis of OA at these sites. 
Treatments for OA are limited. They consist of a combination of non- pharmacological and 
pharmacological approaches, which should be tailored to the individual according to their 
needs and stage of disease. They aim to relieve pain and stiffness and thereby improve 
function. It is recognised that pain arises from both intra-articular structures (bone or 
synovial tissue) and from peri-articular structures such as entheses, bursae or tendons. 
Sensitisation of peripheral nerves and central nervous system changes can also contribute to 
the persistence of pain over time. 
All patients should be offered education, advice and access to information in combination with 
physical approaches (e.g. strengthening exercises and physiotherapy, including aerobic fitness 
training) and lifestyle changes (e.g. weight reduction and dietary manipulation) as 
appropriate. Additional therapies include systemic drugs (e.g. analgesics, anti-inflammatory 
agents, supplements, and, recently, disease modifying treatment such as hydroxychloroquine) 
and surgery.   
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This chapter focuses on treatments that are administered to the joint itself, or in the region of 
the joint. Pain management techniques such as nerve block and transcutaneous electrical 
stimulation are beyond the scope of the article. 
2. Specific therapies 
2.1 Splinting/support 
Orthoses (or braces) are external devices mainly prescribed to modulate mechanical stress 
on a symptomatic joint compartment. They are used in knee and hand OA but not in hip 
OA. For knee OA, they include rest orthoses, knee sleeves and unloading braces. For hand 
OA they include thumb and wrist splints. Insoles are used in hip and knee OA: they include 
cushioned or neutral insoles, which act as shock absorbers; and wedged insoles, which also 
modulate mechanical stress.  
For lower limb OA, the main purpose of orthoses and insoles is to support an unstable joint 
and to help correct alignment (5). In doing so, they reduce pain, reduce load bearing and 
improve physical function. They can also improve proprioception (6) and possibly slow 
disease progression (7). They are particularly recommended in mild or moderate 
unicompartmental knee OA (8,9,10) where varying degrees of frontal or sagittal instability 
and varus or valgus mal-alignment occur, and ideally should be used in combination with 
other therapeutic approaches. The different interventions are described individually below. 
1. Rest orthoses are made from a stiff composite and are intended for joint 
immobilization. They are rarely used in practice however, and there are no clinical trial 
data to suggest effectiveness. Whether they would be helpful in transiently 
immobilising a swollen knee remains uninvestigated (11). 
2. Knee sleeves are functional elastic non-adhesive orthoses that can be used alone or in 
association with various devices and are aimed at patellar alignment or frontal femoro-
tibial stabilisation. Simple neoprene knee sleeves used in medial compartment OA have 
been shown to reduce pain on activity and stiffness but not physical disability in the 
short term (6 months) when compared with no sleeve (12). This does not appear related 
to a local thermic effect. They have also been shown to increase static and dynamic 
balance, which might help prevent falls (13). Heat retaining sleeves (worn for 12 hours 
per day for 4 weeks) do not offer additional therapeutic benefit over standard devices 
(14). Medial patellar strapping has also been shown to reduce pain significantly in 
patello-femoral OA associated with patellar mal-alignment (15).  
3. Unloading knee braces are functional devices indicated in patients with mal-alignment 
secondary to medial or lateral unicompartmental OA. They are composed of external 
stems, hinges and straps and are designed to decrease the compressive load transmitted 
to the diseased compartment by applying an external valgus or varus force respectively. 
Analgesic effect is achieved by improved stability, increased joint opening and possibly 
by reduction in local muscle contractions during gait (7). 
A single randomized controlled trial (RCT) of 110 patients showed that a valgus brace 
significantly improved pain, functional status and disease-specific quality of life at six 
months compared with no intervention in patients with medial compartment knee OA, 
and was more effective than a neoprene sleeve (12). However, a further RCT did not 
confirm its efficacy in pain reduction (16). A subset of patients in this trial found the 
varus brace effective for lateral compartment OA; this is the only trial result supporting 
efficacy of varus bracing. Unloading braces have been shown to improve isokinetic 
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quadriceps strength and gait symmetry (11) and while they significantly improve joint 
proprioception, this does not appear to improve postural control (6).  
The main drawbacks with unloading braces are a variable response rate (39 to 93% of 
patients notice improvement) (11), and discomfort due to heaviness, heat and mobility 
of the device. The latter can also lead to persistent joint instability. In a three-year follow 
up study of 22 patients, the most common complaint was skin irritation affecting 41% of 
patients (17). Long-term compliance is therefore a problem: 20% of patients discontinue 
their brace at 6 months and many discontinue treatment within 1 to 2 years (18). Long 
term efficacy is therefore unknown. The most serious reported side effect is venous 
thromboembolism. 
4. Insoles. There are limited data for the effectiveness of insoles (either laterally wedged or 
neutral) in reducing the symptoms of OA. In one study there was significant decrease in 
non-steroidal anti-inflammatory drug (NSAID) consumption and significantly better 
compliance in the laterally wedged insole group at 6 and 24 months compared to the 
neutral wedge group but there was no significant difference in pain, stiffness and function 
(19). Another study has shown that elastic subtalar strapping significantly reduces pain 
and femoro-tibial angulation at 6 and 24 months compared with traditional laterally 
wedged insoles (20). Adverse effects include low back, popliteal and foot sole pain (21).  
However, given their low cost and relatively better compliance, attention to footwear with 
shock-absorbing properties is worth considering (22).  
5. Thumb Splints. In patients with hand OA, pain and its anticipation is a major factor in 
loss of hand function. Pain reduction should therefore be the primary goal of treatment. 
It appears that 1st carpo-metacarpal (CMC) joint OA contributes more to pain and 
disability than inter-phalangeal joint OA (23). As heavy stresses are placed on the 1st 
CMC joint during pinching and grasping, thumb splints are useful especially if the 
patient has difficulty in performing daily tasks. 
Their efficacy was shown in a systematic review in 2010, which found high to moderate 
evidence for thumb CMC joint immobilization in improving pain and function and moderate 
evidence in improving grip strength (24). A multi-centre trial also showed strong evidence for 
efficacy at twelve months (but not at one month) in terms of improved pain and disability (25).  
There are several different designs of thumb CMC splints (from a short opponens splint 
which supports the 1st CMC and metacarpo-phalangeal (MCP) joint, to a much larger long 
opponens splint which includes both the MCP and wrist joint) (26). As yet it is unclear 
which are considered most comfortable for patients and thus will be worn long term, and 
what degree of support is required at what stage of OA in order to improve pain and 
function effectively (22).  
2.2 Topical non-steroidal anti-inflammatory drugs 
Direct application of topical non-steroidal anti-inflammatory drugs (NSAIDs) in the region 
of a painful joint is a common and recommended treatment in mild to moderate OA 
(8,9,10,22). This treatment is particularly useful in the management of a single painful 
osteoarthritic joint (especially the knee), or when a few hand joints are involved.  It can 
provide a safe and effective alternative to systemic anti-inflammatory therapy. 
Topical NSAIDs act primarily through inhibition of cyclo-oxygenases responsible for 
prostaglandin biosynthesis at the site of pain and inflammation, but might also work 
through peripheral and central desensitisation (27).  Unlike other topical treatments, the act 
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of local rubbing appears less important in achieving a therapeutic effect. Topical NSAIDs 
can be applied over the affected joint up to 2 to 4 times a day depending on the drug, but 
currently are not recommended for continuous use beyond one month.   
There are several different preparations of topical NSAID available, which differ in the 
active drug (diclofenac, ibuprofen, ketoprofen, piroxicam and felbinac), formulation (gel, 
solution, cream, plaster and patch) and the presence of a penetration enhancer to improve 
drug delivery (45.5% dimethylsulfoxide [DMSO] or menthol).  The most commonly studied 
preparations are diclofenac sodium 1% gel (DSG) and diclofenac sodium 1.5% in 45.5% 
DMSO solution (Pennsaid).  
To be effective, a topical NSAID needs to penetrate the skin and enter the circulation or 
additionally be absorbed into the underlying tissue. The formulation with respect to its lipid 
and aqueous solubility (requirements for passing through the stratum corneum and 
epidermal layer respectively) determines the degree of dermal penetration (28). 
Formulations of gels and sprays are more effective than creams.   
Studies show that penetration of the topical NSAID into the intra- and peri-articular 
structures via the local bloodstream gives rise to therapeutic concentrations within these 
tissues without significant systemic absorption (28,29). This accounts for their superior 
safety profile over oral therapy with respect to systemic renal, cardiovascular and 
gastrointestinal toxicity.  
Peak concentrations in the skin are achieved 2 hours after application, with a second peak 10 
hours after application, which is attributed to the systemic circulation. The skin appears to 
act as a ‘reservoir’ from which the drug is distributed to deeper tissues (30). Only 3-7% of 
the applied dose is systemically absorbed (29) and mean plasma concentrations are typically 
5% or less of the level reached following oral administration (31,32). Low systemic 
absorption is evidenced further by the lack of symptom relief in other joints distant to the 
site of application (33).  
With respect to knee osteoarthritis, up until recently there was no research evidence to 
support the long-term use (greater than a month) of topical NSAIDs; a systematic review in 
1998 (34) and two meta-analyses in 2004 (35,36) confirmed that topical NSAIDs were 
superior to placebo for up to two weeks in the treatment of chronically painful conditions 
but not longer. Later trials have however shown more long term efficacy, benefit beyond 4 
weeks was confirmed in a meta-analysis of trials assessing efficacy between 4 and 12 weeks 
(37), and two further recent large high quality RCTs have demonstrated a sustained 
response maintained up to 12 weeks with diclofenac (“DSG” (33) and “Pennsaid” (38)) when 
compared with placebo. A recent RCT has also found topical ibuprofen to be as effective as 
oral ibuprofen and other NSAIDs for 12 months (39).  
Currently there is insufficient evidence to compare efficacy of topical to oral administration 
of the same NSAID. The meta-analysis of RCTs in 2004 found that overall topical NSAIDs 
were less effective than oral NSAIDs (36). Two recent studies comparing topical diclofenac 
(in DMSO) with oral diclofenac in patients with knee OA have however demonstrated 
equivalent efficacy (40,41).  
Placebo controlled trials and head to head studies with oral NSAIDs also show efficacy of 
topical NSAIDs in finger joint OA: hence they are preferred to systemic therapy, especially 
for mild to moderate OA and when few joints are involved (42).  
The main side effect of topical anti-inflammatory treatment is local application site reactions 
such as dry skin, rash, pruritis and burning (36,37). They are short-lived and minor 
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however, and usually resolve when application is discontinued. Studies show that local 
adverse events are reported with equal frequency for topical NSAIDs and placebo 
preparations; hence they appear not to be related to the NSAID itself (35). Safety between 
different topical agents has not been studied. However, three 12-week trials showed a 
greater incidence (5 to 8 fold higher) of local application site reactions with diclofenac in 
DMSO solution (26-42%) compared with DSG (5.1%) (33). 
Compared to oral NSAIDs, topical therapy is associated with fewer systemic adverse events 
and gastro-intestinal side effects (33,35,40,41). However, data regarding gastro-intestinal 
safety and tolerability of topical NSAIDs in older patients (over the age of 50 years) are 
conflicting. Some studies report minor side effects to be infrequent, including the two-year 
RCT comparing topical to oral ibuprofen (39,43); but a recent systemic review has 
demonstrated gastro-intestinal adverse events in 15% and local skin reactions in 39.3% of 
patients receiving topical NSAIDs including skin sensitivity, contact dermatitis and 
photodermatitis (44). 
While topical NSAIDs should be considered with paracetamol as first line treatment ahead 
of oral NSAIDs, COX-2 inhibitors or opioids in view of their efficacy and relative safety, 
further studies are needed to confirm their long-term efficacy and use in bilateral knee OA. 
Their use in older patients also might still require a degree of caution until further data 
demonstrating their safety profile in this age group become available. 
2.3 Topical counter-irritants 
Topical counter-irritants or rubefacients are agents that are frequently applied locally to 
relieve musculoskeletal pain in the extremities. The most commonly used rubefacient is 
salicylate, but this class of agent also includes nicotinate esters. Topical capsaicin is 
commonly considered to be a rubefacient; however its mechanism of action is sufficiently 
different for this treatment to be described separately. 
The principal action of rubefacients is to act as a skin irritant. This results in reddening from 
vasodilatation and increased blood flow, but also leads to a soothing sensation of warmth 
i.e. counter-irritation. It is still unclear whether topical salicylates additionally relieve pain 
via cyclo-oxygenase inhibition, but there is little evidence that there is significant systemic 
absorption (45). This is consistent with the fact that no benefit is found using a rubefacient 
applied distal to the site of pain (46). Pain may also be offset or altered in the underlying 
muscle, joint and tendon by irritation of the sensory nerve endings (47). More recently there 
is evidence to suggest that salicylates and other rubefacients may act via the transient 
receptor potential (TRP) ion channels involved in thermal and pain sensation (48,49). 
Although topical rubefacients containing salicyclate are widely used in England (almost 1.8 
million prescriptions issued in 2006) (50), there is currently no evidence to support their 
prescription for chronic musculoskeletal pain. A Cochrane analysis in 2009 of six studies of 
rubefacients in chronic conditions such as osteoarthritis has shown that they produced 
significant benefit compared with placebo at 14 days, with 1 in 6 individuals achieving 50% 
pain relief (51). This compares poorly with topical NSAIDs however, where the number needed 
to treat (NNT) is 3.1 compared to placebo. Additionally their efficacy may be over-estimated as 
adequate blinding is not possible with any trial involving a rubefacient, the mechanism of 
action is through local irritation and any sham preparation, which attempts to mimic this, 
would be a rubefacient itself.  However, placebo gels in trials were rubbed on to the skin in the 
same way as the active treatment overcoming any additional therapeutic effect of rubbing (52). 
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Based on limited data, rubefacients appear well tolerated and local adverse effects are 
uncommon in the short term (2% of patients) (51,52). Currently they are usually used as 
adjuvants to other therapies, such as oral analgesics, support bandages, rest, ice, and 
compression, and may be useful for patients who cannot tolerate oral analgesics (52). RCTs 
are needed to support their clinical use with respect to long-term efficacy and safety 
especially in osteoarthritis, which is a chronically painful condition. Most trials have lasted 
14 days only and the longest trial spanned 28 days (52). Consequently rubefacients are not 
recommended in the UK in osteoarthritis although this recommendation has been based on 
a small number of limited studies (22). 
2.4 Topical capsaicin 
Topical capsaicin (0.025%) cream can be used to treat pain from osteoarthritis and 
rheumatoid arthritis. A higher dose (0.075%) is used in the treatment of neuropathic pain. 
The preparations contain capsaicin, a lipophilic alkaloid extracted from chilli peppers that 
has an extremely potent irritant effect. They work by initially selectively activating and 
sensitising c-nociceptors in the skin by binding the transient receptor vanilloid type 1 (TRPV 
1) cation channel (53). Substance P is released which causes local irritation; however with 
repeated applications, levels are depleted leading to reversible desensitization of pain fibres 
and eventual degeneration of epidermal nerve fibres resulting in hypoalgesia (54). Although 
topical capsaicin is better than placebo for treatment of chronic pain, a meta-analysis of 
topical capsaicin (0.025%) or plaster for chronic musculoskeletal pain calculated the NNT at 
4 weeks to be 8.1 for a 50% reduction in pain suggesting that capsaicin is only marginally 
effective (55).  
In general therefore topical capsaicin is best employed as an adjunct to other modes of 
therapy. It should be used for 3 to 4 weeks (applied 4 times daily) to achieve maximal 
benefit. A transient local burning sensation (which can be intense), stinging or erythema at 
the application site are common (40%) (10), and lead to 1 in 10 patients discontinuing the 
treatment (55) however. Systemic events are rare. 
2.5 Thermotherapy 
The local application of heat or cold (cryotherapy) to a painful joint has been used for many 
years in the rehabilitation of patients with OA to relieve pain, stiffness and oedema. 
Cryotherapy is usually administered by application of cold packs or massage with ice over 
painful areas or acupoints (56). Cold application helps to reduce pain and swelling by 
causing temporary vasoconstriction and a reduction in local blood flow. This may in turn 
help improve range of motion and function (57). Heat therapy is used to reduce pain and 
stiffness by possibly improving circulation and relaxing muscles.  However there are 
concerns that increased blood flow may worsen inflammation and oedema. Common 
methods of superficial heat administration are electrical heating pads, application of hot 
packs, towels or wax, or immersion in warm water or wax baths. 
Supporting evidence for the efficacy of this mode of treatment remains very limited. For 
knee osteoarthritis, ice massage may be a useful adjunct for pain relief and cold packs may 
be used to lessen knee oedema  (Cochrane review of three RCTs in 2003, involving 179 
patients) (58). Ice massage for 20 minutes, 5 times a week for 3 weeks had a clinically 
significant effect on knee strength (29% improvement) with a statistically significant 
improvement in range of movement (8% relative difference) and function (11% relative 
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difference) after two weeks of treatment (59) but not at three weeks given three times a week 
(60). Ice packs did not affect pain significantly compared to controls; however ice massage 
did have a significant effect. Cold packs also lead to a significant reduction in knee swelling 
but this has not been seen with hot packs (61). Some studies have shown that heat therapy 
for knee OA used for 20 minutes every other day for four weeks can significantly improve 
pain and disability but not stiffness (62). There have been no controlled trials of cryotherapy 
in hip OA.   
There are no experimental studies to examine the role of cryotherapy in hand osteoarthritis.  
However, a systematic review in 2010 found three studies that had examined the role of heat 
therapy in 174 patients (63). There is weak evidence for the role of paraffin wax in pain 
reduction, improved range of movement and function, and moderate level evidence to 
support the use of low level continuous heat wrap and steam treatments for pain reduction 
and improved grip strength (64). Local application of heat prior to exercise may be helpful 
in knee OA; however direct research evidence for the benefit of local application of heat as a 
pretreatment or in combination with other physical therapies for hand OA is lacking (42). 
Although further studies are required to determine their efficacy, heat and cold therapies 
are easy, non-invasive treatments with very few adverse events, and therefore can be 
considered as an adjunct to core treatment in hand and knee OA.  
2.6 Joint aspiration 
Aspiration of synovial fluid from a swollen joint (e.g. aspiration of knee) can provide 
temporary relief in pain and stiffness, although effusions usually re-accumulate unless 
steroid is injected. Aspiration of cystic fluid in cystic OA of joints similarly often provides 
symptomatic relief, but again fluid tends to re-accumulate. 
2.7 Intra-articular corticosteroid 
Intra-articular (IA) corticosteroid injections have been widely used to treat symptomatic 
peripheral joint OA for many years.  The corticosteroid exerts its anti-inflammatory effect by 
interrupting the immune and inflammatory cascade at several levels. Local delivery of high 
doses of corticosteroid minimises systemic toxicity and can result in rapid improvement in 
symptoms during acute or severe symptom flares, especially in knee and hand OA. 
Corticosteroid preparations differ in solubility and potency:  more soluble preparations 
have a shorter duration of action, e.g. hydrocortisone acetate, compared to longer acting 
emulsion based preparations, which are only slightly soluble, e.g. methlyprednisolone 
acetate (MPA) or relatively insoluble, e.g.triamcinolone acetonide (TCA). Longer acting 
preparations are more effective for intra-articular injections as they remain in the joint 
longer, but there are few randomised, controlled trials comparing different IA 
corticosteroids.  In a double blind RCT of 57 patients with symptomatic knee OA 
comparing TCA 20mg with MPA 40mg, there was a greater reduction in pain compared 
with baseline at 3 weeks with TCA compared to MPA, but this was only maintained at 8 
weeks in the MPA group despite TCA being less soluble (65). In practice the choice of 
agent is usually based on local availability and cost. The dose-response relationship has 
not been systematically studied. 
Most manufacturers advise against corticosteroid dilution with local anaesthetic (e.g. 
lignocaine) because of the risk of clumping and precipitation of steroid crystals.  
However this remains common practice and provides additional benefits:  there is early 
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temporary relief of symptoms; it verifies delivery of steroid to site of pain (66); and it 
dilutes the suspension, enabling even distribution within the joint, (especially in 
shoulder joint injections), and hence avoids placement of highly concentrated fluid into a 
single area. 
Several randomised controlled trials (67-70) and one Cochrane systematic review (71) have 
shown significant short-term efficacy (between 1 to 4 weeks) in terms of pain reduction for a 
single IA corticosteroid (TCA, MPA and cortivazol) over placebo in knee OA although 
effects on function appear less marked. There was no significant benefit at 4 to 24 weeks 
post injection. Hence IA corticosteroids work rapidly, but the effects are mostly short-lived. 
The lack of a sustained response over placebo in these studies might relate to lower than 
recommended steroid doses used, and a strong beneficial effect seen in patients receiving IA 
placebo injection. In clinical practice, IA steroid injections provide rapid short-term pain 
relief to settle flares of pain and permit patients to begin other interventions such as 
quadriceps strengthening exercises.  
The benefit of IA corticosteroid injections to the hip remains inconclusive. One small RCT of 
35 patients examining the role of TCA in patients awaiting hip replacement showed good 
pain relief at one month, but this was not maintained, and in 8.5% symptoms deteriorated 
(72). Another RCT showed significant improvement by IA MPA 40mg at 2 weeks compared 
with placebo 0.9% saline injection, but efficacy was lost at 3 months (73).  
The efficacy of IA 1st CMC joint injection was evaluated in a trial of 40 patients with 
primary moderate to severe OA, randomized to either 0.25mls TCA (5mg) or an 
equivalent volume of 0.9% saline. No clinical benefit was gained compared to placebo 
injection (74). A further prospective study of 30 patients with radiographically staged 
hand OA has shown long-term benefit (18 months) with a single IA 1st CMC joint injection 
and subsequent splinting for 3 weeks, in 80% of patients with early radiographic disease 
i.e preserved joint space and minimal other changes. In patients with more 
radiographically advanced OA with osteophytes and joint space narrowing, sustained 
pain relief was less reliably achieved (75).  
While IA corticosteroids have marked anti-inflammatory effects and reduce the volume of 
synovitis in OA (73), disease factors which might relate to the presence of inflammation 
have not been found to determine clinical response including local heat and synovial 
thickening (70), and synovial fluid (SF) volume and leucocyte count (69).  Furthermore the 
presence of a knee effusion does not appear to predict response either (67,70). In one study 
prior synovial fluid aspiration did lead to a greater reduction in pain (69); however this may 
have been related to less steroid dilution by synovial fluid and more accurate placement of 
the IA injection confirmed by prior synovial fluid aspiration (76). Hence the presence of a 
knee effusion is not necessarily an indication for corticosteroid injection unless it causes 
significant restriction in movement. (22) 
Additionally a steroid response is not confined to joints with clinical evidence of 
inflammation (70). This appears not to be related to inaccuracy in detecting inflammation on 
clinical examination; a recent ultrasound scanning study showed that patients with non-
inflammatory features on ultrasound derived more prolonged benefit compared to patients 
with inflammatory features (77).  
The risks in IA steroid injection are generally small but the following potential side effects 
can occur: 
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1. Post-injection crystal-induced synovitis can occur in 2 to 6% of patients. It is usually 
observed within 24 hours of injection, and spontaneously resolves in 1 to 3 days (78). It 
is usually managed by analgesic therapy or ice packs. Flares have also been reported 
following saline injection suggesting that other factors such as injection technique may 
be responsible (67,69). 
2. Iatrogenic infection is rare, with a reported incidence between 1 in 3000 to 1 in 50 000 
(79). Symptoms usually occur within 3 to 4 days of injection. Aseptic technique and 
withholding injection in at risk patients should minimise this potential serious 
complication. 
3. Lipoatrophy secondary to subcutaneous deposition of steroid is more common with 
less soluble preparations and was found to occur in 0.6% of patients in a prospective 
study of intra- and peri-articular injections of methylprednisolone acetate (80). Hence 
longer acting preparations are generally avoided in small joint injections where accurate 
placement is technically difficult. 
4. Local effects including tendon weakening/ rupture, muscle wasting, skin pigmentation 
changes, nerve and blood vessel damage can be minimised by more accurately directed 
injections. 
5. Systemic effects vary. Facial flushing is relatively frequent (40% in one study) (81) and 
may occur after a few hours. Diabetic control may be temporarily disturbed but not 
significantly (82). Corticosteroid-induced osteoporosis does not appear to be a major 
concern due to lack of net impact on bone resorption. Anaphylaxis is extremely rare 
(81). 
Concern regarding long-term effects of repeated injection, such as risk of progressive 
articular cartilage damage, has limited the number of injections given to any particular joint: 
the general consensus is for no more than 3 to 4 per year. While animal studies have shown 
steroid induced chondrocyte degeneration (83), data to support this recommendation in 
clinical practice are lacking. In a randomised prospective trial of patients receiving TCA 
injections every 3 months for up to 2 years for knee osteoarthritis, no evidence of increased 
loss of joint space was observed (84). Similarly there are very few reports of osteonecrosis, 
with no convincing causal relationship identified.  Unpublished experience does however 
suggest that there may be an increased risk of osteonecrosis of the femoral head following 
such injections into the hip joint. 
Repeated intra-articular corticosteroid injections do not provide long-term benefit (76), and 
it is generally accepted that other treatment modalities should be sought if patients require 
frequent or numerous injections.  
2.8 Intra-articular hyaluronic acid/ hyaluronan 
Endogenous hyaluronan, previously known as hyaluronic acid (HA), is a large linear 
glycosamino-glycan.  It is a major non-structural component of both the synovial and cartilage 
extracellular matrix and of synovial fluid. Key functions in the joint are to confer viscoelasticity 
and lubrication, and to help maintain tissue hydration and protein homeostasis by preventing 
large fluid movements (22). OA is associated with a decrease of HA content in the synovial 
fluid (85). The therapeutic goal of intra-articular viscosupplementation with HA is therefore to 
restore the natural protective function of hyaluronan in the joint.  
The mechanism by which HA exerts its therapeutic effect, if any, is not certain. Intra- 
articular residency is short (hours), but the reported benefit is long (months). The short-term 
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mode of action might be based on the pain relieving effect of the viscoelastic fluid in the 
affected joint. In the long term a sequence of events might be triggered which restores the 
trans-synovial flow and subsequently the metabolic and rheological homeostasis of the joint 
(86). However there is minimal evidence for a role in long term disease modification (8).  
Commercial preparations of HA have the same structure as endogenous HA, although 
cross-linked HA molecules (known as hylans) were later engineered in order to obtain 
greater elasto-viscosity and intra-articular dwell-time. There are several formulations 
available (Artz, BioHy, Durolane, Hyalgan, Synvisc, Suvenyl, Orthovisc, Replasyn and 
Suplasyn) which vary in their molecular weight (2 to over 7 million KDA).  This difference is 
thought to be of importance with respect to the volume and number of injections needed, 
and the length of time the preparation remains in the joint. Higher molecular weight 
preparations, such as Hylan G-F 20 (Synvisc), seem to be more effective than lower-
molecular-weight preparations in this respect (87).  
Although there are a large number of studies in the literature, evidence for the efficacy of 
HAs is difficult to interpret because studies have used different molecular weights of HA 
and different injection schedules, and because of poor trial design. In addition, the benefit 
from placebo saline injections was high in some of the studies. Overall, hyaluronans and 
hylan derivatives seem to be superior to placebo in terms of efficacy (including pain relief, 
function and patient global assessment) and quality of life outcomes in patients with knee 
OA at different post-injection periods, but especially at 5 to 13 weeks after the last of a series 
of 3 to 5 injections (86). Clinical trials do not suggest that sub-groups of osteoarthritis 
patients may have greater benefit; however this would be of research interest given the high 
cost of this particular treatment (22). Data from the Cochrane meta-analysis suggest that IA 
therapy with hyaluronans may have a more prolonged effect than IA corticosteroids (86). 
Adverse effects are rare but include a transient increase in pain and very rarely a frank 
arthritis flare with knee effusion. There do not appear to be any systemic side effects.  
In hip OA, no significant differences between hyaluronans and placebo were reported at any 
time point by a RCT evaluating efficacy and function outcomes, but the effect was better in 
patients without an effusion (88). There was no significant difference between hyaluronan 
and corticosteroid injection either (88). Similarly, hyaluronan and corticosteroid injections 
perform similarly with respect to efficacy and function in hand OA (89).  
Overall the evidence for HA efficacy is mostly in knee OA, with a slower onset of action but 
a more durable response than IA corticosteroid injection. It is a safe treatment.  However its 
widespread use is limited by cost. It is usually offered to patients who are not fit for or 
would like to delay surgical intervention, and in patients who require repeated IA 
corticosteroid injections. 
2.9 Acupuncture 
Accupuncture is a recommended modality of therapy for symptomatic treatment of patients 
with knee and hip OA. It involves treatment with fine filiform stainless steel needles of 0.25- 
0.35mm diameter. Typically six needles are placed near the painful area and possibly elsewhere 
and are either manipulated to produce a ‘needle sensation’ or stimulated electrically 
(electroacupuncture) for up to 20 minutes. A course of treatment usually consists of six or more 
sessions. The response can be variable, the reasons for which are not well understood. Potential 
underlying neurophysiological mechanisms are complex. The ‘gate control theory’ and release 
of endogenous opioids are possible explanations for the apparent analgesic effect (10). 
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Although an earlier systematic review of acupuncture in patients with OA at various 
peripheral sites did not show it to be any better than sham controls (90), several randomized 
trials report benefit in knee OA over sham acupuncture (91-93) and standard treatment (94).  
A systematic review in 2001 of 7 RCTs including 393 patients (95) found that acupuncture 
significantly improved pain compared with sham acupuncture, but not function (92,93). 
However, it was not found to be more effective than physical therapy or than being on a 
waiting list to receive acupuncture (94,96). The benefit appears short to medium term (6-12 
weeks); the few studies with long-term follow up did not show benefit at 26 weeks (91,94). 
Combining acupuncture with a course of advice and exercise has not been shown to provide 
any additional benefit (97). Acupuncture of peripheral joints appears safe (98). Mild adverse 
effects occur in 7% of patients (99,100), but serious side effects are rare (101).  
2.10 Trigger point injection 
In many forms of arthritis, localised areas of thickening and tenderness in cutaneous and 
other soft tissues can be found.  These have been referred to by a number of different names, 
including interstitial fibrositis, myofasciitis and myofascial trigger points (102-104).  They 
are also well described by acupuncturists (105).  Some are found clinically in cutaneous and 
subcutaneous tissue at sites near to or distant from inflamed or painful joints, typically in 
areas of a limb proximal to an affected joint, such as in the upper part of the rectus femoris 
in patients with knee pain, and in paraspinal regions in the cervical and lumbar areas (106).   
The term trigger point injection (TPI) refers to direct injection of a substance into the trigger 
point itself, or into the skin or soft tissue over the trigger point (indirect needling); or to dry 
needling of either of these areas. The main objective is to inactivate the trigger point thereby 
reducing pain and restoring function. However, the aetiology and pathogenesis of trigger 
points have yet to be elucidated, and the precise mechanism by which TPI inactivates the 
trigger point is still unknown (107). 
Optimal technique and treatment regimen for TPI varies between practitioners, and is 
largely based on clinical experience. Treatment begins with identifying the trigger point; the 
area of maximal tenderness and immobilising the muscle between the thumb and forefinger. 
Generally a sterile small gauge needle is then introduced into the trigger point. Correct 
identification is supported by a twitch in the affected muscle, exacerbation of pain and the 
presence of referred pain (108). 
Clinicians have used local anaesthetic, anti-inflammatory agents (long-acting corticosteroid, 
acetylsalicylate and ketorolac), saline and water (104,108-113). Injecting a trigger point is 
painful and the addition of a local anaesthetic to the injected fluid can help reduce pain and 
irritation (114,115).  
A systematic review of the efficacy of TPI to treat chronic non-malignant musculoskeletal 
pain (such as whiplash syndrome or chronic head, neck, shoulder, and back pain) of more 
than three months’ duration found that TPI relieved symptoms when used as a sole 
treatment for patients, regardless of the injectant used, but was not more effective than other 
less invasive treatments such as laser and ultrasound (107).  
The efficacy of TPI as a treatment for osteoarthritis is not well described; and as most studies 
have looked at its role as a sole treatment rather than in the adjunct capacity in which it is 
routinely used in clinical practice, its effectiveness might be underestimated. One study 
showed that intra-articular injection combined with lidocaine TPI of any of the 15 leg muscle 
trigger points was more effective than intra-articular injection alone in relieving pain and 
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improving knee function in a highly selected group of older patients with knee osteoarthritis 
(116). Except for the rare occurrence of muscle atrophy at the injection site, very few adverse 
events are reported with TPI and it is currently recommended as an adjunct therapy in 
osteoarthritis. 
2.11 Subcutaneous sodium salicylate injection 
Trigger point injection using sodium salicyclate has also been studied. In a large 
uncontrolled study Fox reported a good response from injecting 0.5% sodium salicylate into 
superficial areas of tender soft tissue thickening:  using multiple injections, he recorded an 
improvement in symptoms in 79% of patients at 12 weeks (117). Most of these subjects had 
osteoarthritis. 
Following similar preliminary observations in our group, we performed a pilot study, in 
which 16 patients with OA of the first (thumb) CMC joint were treated with injections of 
0.5% sodium salicylate or saline into similar areas of superficial soft tissue thickening (118).  
There was a significant improvement in pain score in both groups.  The improvement was 
better maintained in the patients that received salicylate.  A subsequent double-blind study 
of 40 patients with the same condition showed superiority of sodium salicylate injections 
over sham injections (119).  Pain and tenderness during follow up were both significantly 
lower in the active treatment group compared with the sham group. 
The chief limitation in studies of this kind is the imperfect nature of the control treatment.  
However, in the sham-controlled study, the improvement in the active treatment group was 
sustained for as long as 13 weeks, suggesting that an effect greater than placebo was being 
observed.  Furthermore, there was no significant correlation in the active group between the 
pain of the injections and response in terms of pain in the joint. 
The mechanism of action of this treatment is uncertain.  The injected patches are distant 
from the affected joint.  It is possible that the salicylate causes a change in the control of 
pain, perhaps through a modification of central sensitisation.  This would be consistent with 
reports by patients of improvement in symptoms within minutes.  The treatment could 
modify the neurogenic control of inflammation, which may be disturbed in musculoskeletal 
disease (120,121).  One way in which this might occur could be through changes in the 
expression or transport of neurogenic peptides (122), brought about by an irritant effect of 
the salicylate, similar to that of topical capsaicin (55,123).  A systemic anti-inflammatory 
effect is unlikely, since similar injections of salicylate at other sites fail to produce any effect 
on the symptoms of osteoarthritis (Mackworth-Young C.G., personal observation). 
It could be that sodium salicylate injection therapy acts in a manner similar to acupuncture, but 
achieves a more prolonged effect because a substance is injected into the tissues that results in a 
sustained stimulus.  Many of the injected patches occur at standard acupuncture sites. 
Sodium salicylate therapy is inexpensive, and can be administered by general practitioners 
and trained nurses.  The studies on this treatment also suggest areas for further scientific 
enquiry in the regulation of pain and inflammation in osteoarthritis. 
3. Conclusions 
There are many local therapies available for the treatment of patients with limb joint OA.  
Some are well established, such as intra-articular corticosteroid. Some are relatively new, 
and show promise for further development.  
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Most of them are primarily symptomatic treatments, which need to be tailored to the 
individual’s preference and tolerance. Many of them function well as adjuncts to other 
treatments, such as systemic analgesics or anti-inflammatory agents.  Given the chronicity of 
OA however, they are likely to be required over long periods of time, either continuously or 
as episodic treatment during symptom flares. Long-term efficacy data are largely missing, 
although the therapies appear to be generally safe. Furthermore studies for costly 
interventions with proven efficacy such as hyaluronan injections are needed to identify 
subsets of patients who would benefit most from the treatment to allow more targeted use. 
It is uncertain if some treatments may modify medium or long-term outcome. For example 
in inflammatory OA of small finger joints, it is not clear whether intra-articular steroid 
injection hastens the settling down of the inflammation (which tends to happen anyway), 
and thus reduces the amount of joint damage. Similarly, effects of topical NSAIDs, 
acupuncture and subcutaneous sodium salicyclate injections on disease modulation are 
unknown. Longitudinal studies on these treatments may answer these questions. 
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